Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To determine the long-term nephroprotective potential of treatment with sparsentan as
compared to an angiotensin receptor blocker in patients with primary and genetic focal
segmental glomerulosclerosis (FSGS).